14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
SVRE vs MLAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SVRE carries a Unified Composite Score of 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin), whereas MLAB carries 41.6/100 (SELL) at $135.27 (24.9x Forward P/E, 10.4% operating margin).
Defensive Composite Rating Caution: Although MLAB compares more favorably head-to-head, both SVRE (39.3/100 SELL) and MLAB (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: SVRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile MLAB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SVRE vs MLAB. Trailing 12-month operating profitability (SVRE 0.0% vs MLAB 10.4%) and valuation multiples (SVRE N/M vs MLAB 24.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Scientific & Technical Instruments value chain with $781.3M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment54.4% of Rev ($137M)
90D Engineering Disclosures0 Published
Investor FAQ SVRE vs MLAB Key Questions & Quantitative Answers
As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SVRE carries a Unified Composite Score of 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin), whereas MLAB carries 41.6/100 (SELL) at $135.27 (24.9x Forward P/E, 10.4% operating margin). Defensive Composite Rating Caution: Although MLAB compares more favorably head-to-head, both SVRE (39.3/100 SELL) and MLAB (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SVRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile MLAB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MLAB leads the Growth & Scale pillar: SVRE posts -63.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (-41.1% gross margin, 0.0% operating margin), compared with MLAB at +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin). On trailing 12-month operating scale, SVRE generates $2.0M in USD-normalized revenue versus $251M for MLAB. In operating R&D and SG&A reinvestment, SVRE deploys N/A (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($137M) (0 disclosures) for MLAB.
MLAB screens cheaper on headline valuation multiples. SVRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (unreported EBITDA margin), whereas MLAB trades at 24.9x Forward P/E, 119.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRE (-151.1% ROE) versus MLAB (3.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SVRE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 190% Vol realized risk). By comparison, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.14β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.